|
|
Article: Allergan Announces Positive Top-Line Results from Phase III BOTOX(R) Headache Program.
- Article from:
- Business Wire
- Article date:
- September 11, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- Phase III Studies Show Statistically Significant Decrease in Number of Headache Days --
IRVINE, Calif. -- Allergan, Inc. (NYSE: AGN) today announced that it has completed a top-line analysis of its two Phase III clinical trials exploring the use of BOTOX([R]) (botulinum toxin type A) for the prophylactic treatment of headache in adults suffering from chronic migraine - i.e., headaches and/or migraines that occur on 15 or more days each month.
BOTOX([R]) is the first therapy being investigated for this extremely debilitating condition of chronic migraine, which is estimated to affect between 1.2 and 3.6 million people in the United States1a,b.
...